Skip to search formSkip to main contentSkip to account menu

nafamostat mesilate

Known as: Nafamostat Dimethanesulfonate, Nafamostat Mesylate, 6-Amidino2-naphthyl 4-guanidinobenzoate 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Objectives: A randomized controlled trial was conducted to clarify whether continuous regional arterial infusion (CRAI) of… 
2010
2010
BACKGROUND Recent studies suggest that intraluminal pancreatic enzymes play a major role in the initiation of the inflammatory… 
2009
2009
PURPOSE Gemcitabine is currently the standard first-line chemotherapeutic agent for pancreatic cancer. However, chemoresistance… 
2009
2009
BACKGROUND The primary end points of this study were to determine the dose-limiting toxic effects (DLTs), maximum tolerated dose… 
2004
2004
Nafamostat mesilate (NM) is a serine-protease inhibitor that is rapidly eliminated from the circulation and accumulated in the… 
2003
2003
Intravenous injection of ioxaglate (4 g iodine kg−1), an iodinated radiographic contrast medium, caused a marked protein… 
1995
1995
To the Editor: Nafamostat mesylate (6-amidino-2-naphthyl p-guanidinobenzoate, dimethanesulfonate; molecular weight, 540) is a… 
1994
1994
1 The present experiments were undertaken to determine the mechanism(s) of hyperkalaemia caused by nafamostat mesilate (NM), a… 
1993
1993
1 To determine the mechanism(s) of hyperkalemia caused by nafamostat mesilate (NM), a serine‐protease inhibitor, we investigated… 
1989
1989
SummaryWe examined the ability of a highly potent synthetic protease inhibitor, nafamostat mesilate (FUT-175), to protect the rat…